Vahidreza Ostadmohammadi

Vahidreza Ostadmohammadi

Auto-generated profile, based on publicly available information

Vahidreza Ostadmohammadi

Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2019 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
VOVahidreza Ostadmohammadi
Vahidreza Ostadmohammadi
MJMehri Jamilian
Mehri Jamilian
FBFereshteh Bahmani
Fereshteh Bahmani
ZAZatollah Asemi
Zatollah Asemi
The aim of this study was to determine the effect of vitamin D and probiotic co-administration on mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome (PCOS). This randomized, double-blinded, placebo-controlled clinical trial was carried out on 60 subjects, aged 18–40 years old. Subjects were randomly allocated to take either 50,000 IU vitamin D every 2 weeks plus 8 × 109 CFU/day probiotic (n = 30) or placebo (n = 30) for 12 weeks. Vitamin D and probiotic co-supplementation, compared with the placebo, significantly improved beck depression inventory [β (difference in the mean of outcomes measures between treatment groups) − 0.58; 95% CI, − 1.15, − 0.02; P = 0.04], general health questionnaire scores (β − 0.93; 95% CI, − 1.78, − 0.08; P = 0.03) and depression, anxiety and stress scale scores (β − 0.90; 95% CI, − 1.67, − 0.13; P = 0.02). Vitamin D and probiotic co-supplementation was associated with a significant reduction in total testosterone (β − 0.19 ng/mL; 95% CI, − 0.28, − 0.10; P < 0.001), hirsutism (β − 0.95; 95% CI, − 1.39, − 0.51; P < 0.001), high-sensitivity C-reactive protein (hs-CRP) (β − 0.67 mg/L; 95% CI, − 0.97, − 0.38; P < 0.001) and malondialdehyde (MDA) levels (β − 0.25 μmol/L; 95% CI, − 0.40, − 0.10; P = 0.001), and a significant increase in total antioxidant capacity (TAC) (β 82.81 mmol/L; 95% CI, 42.86, 122.75; P < 0.001) and total glutathione (GSH) levels (β 40.42 μmol/L; 95% CI, 4.69, 76.19; P = 0.02), compared with the placebo. Overall, the co-administration of vitamin D and probiotic for 12 weeks to women with PCOS had beneficial effects on mental health parameters, serum total testosterone, hirsutism, hs-CRP, plasma TAC, GSH and MDA levels. This study was retrospectively registered in the Iranian website ( www.irct.ir ) for registration of clinical trials ( IRCT20170513033941N37 ).

1 February 2019 in Clinical Nutrition
Verified
Journal Article
Closed access
FRFariba Raygan
Fariba Raygan
VOVahidreza Ostadmohammadi
Vahidreza Ostadmohammadi
FBFereshteh Bahmani
Fereshteh Bahmani
RRRussel J. Reiter
Russel J. Reiter
ZAZatollah Asemi
Zatollah Asemi

19 June 2018 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
FRFariba Raygan
Fariba Raygan
ZRZohreh Rezavandi
Zohreh Rezavandi
FBFereshteh Bahmani
Fereshteh Bahmani
VOVahidreza Ostadmohammadi
Vahidreza Ostadmohammadi
MMMohammad Ali Mansournia
Mohammad Ali Mansournia
ZAZatollah Asemi
Zatollah Asemi
Background: This study was conducted to evaluate the effects of probiotic supplementation on metabolic profiles in diabetic patients with coronary heart disease (CHD). Methods: This randomized, double-blind, placebo-controlled trial was performed among 60 diabetic patients with CHD, aged 40–85 years at a cardiology clinic in Kashan, Iran, from October 2017 through January 2018. Patients were randomly divided into two groups to take either probiotic supplements (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were taken at the beginning of the study and after the 12-week intervention to determine related markers. Results: After 12-week intervention, probiotic supplementation significantly decreased fasting plasma glucose (β − 20.02 mg/dL; 95% CI − 33.86, − 6.17; P = 0.005), insulin (β − 2.09 µIU/mL; 95% CI − 3.77, − 0.41; P = 0.01), insulin resistance (β − 0.50; 95% CI − 0.96, − 0.03; P = 0.03) and total-/HDL-cholesterol ratio (β − 0.27; 95% CI − 0.52, − 0.03; P = 0.02), and significantly increased insulin sensitivity (β 0.008; 95% CI 0.001, 0.01; P = 0.02) and HDL-cholesterol levels (β 2.52 mg/dL; 95% CI 0.04, 5.00; P = 0.04) compared with the placebo. Moreover, probiotic supplementation led to a significant reduction in serum high sensitivity C-reactive protein (β − 0.88 mg/L; 95% CI − 1.39, − 0.38; P = 0.001), and a significant elevation in total antioxidant capacity (β 108.44 mmol/L; 95% CI 47.61, 169.27; P = 0.001) and total glutathione levels (β 45.15 µmol/L; 95% CI 5.82, 84.47; P = 0.02) compared with the placebo. Probiotic supplementation did not affect other metabolic profiles. Conclusions: Overall, we found that probiotic supplementation for 12 weeks had beneficial effects on glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, biomarkers of inflammation and oxidative stress in diabetic patients with CHD. Trial registration Clinical trial registration number http://www.irct.ir: IRCT2017082733941N5

1 June 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
FRFariba Raygan
Fariba Raygan
VOVahidreza Ostadmohammadi
Vahidreza Ostadmohammadi
FBFereshteh Bahmani
Fereshteh Bahmani
ZAZatollah Asemi
Zatollah Asemi

1 May 2019 in Journal of Affective Disorders
Verified
Journal Article
Closed access
ASAzade Shabani
Azade Shabani
FFFatemeh Foroozanfard
Fatemeh Foroozanfard
EKElham Kavossian
Elham Kavossian
EAEsmat Aghadavod
Esmat Aghadavod
VOVahidreza Ostadmohammadi
Vahidreza Ostadmohammadi
ZAZatollah Asemi
Zatollah Asemi

14 May 2019 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
MJMehri Jamilian
Mehri Jamilian
FFFatemeh Foroozanfard
Fatemeh Foroozanfard
NMNaghmeh Mirhosseini
Naghmeh Mirhosseini
EKElham Kavossian
Elham Kavossian
EAEsmat Aghadavod
Esmat Aghadavod
ZAZatollah Asemi
Zatollah Asemi
Purpose: The aim of the current study was to evaluate the effect of melatonin administration on clinical, hormonal, inflammatory, and genetic parameters in women with polycystic ovarian syndrome (PCOS). Methods: The present randomized, double-blinded, placebo-controlled clinical trial was conducted among 56 patients with PCOS, aged 18–40 years old. Subjects were randomly allocated to take either 5 mg melatonin supplements (n = 28) or placebo (n = 28) twice a day for 12 weeks. Results: Melatonin administration significantly reduced hirsutism (β −0.47; 95% CI, −0.86, −0.09; P = 0.01), serum total testosterone (β −0.11 ng/mL; 95% CI, −0.21, −0.02; P = 0.01), high-sensitivity C-reactive protein (hs-CRP) (β −0.61 mg/L; 95% CI, −0.95, −0.26; P = 0.001), and plasma malondialdehyde (MDA) levels (β −0.25 μmol/L; 95% CI, −0.38, −0.11; P < 0.001), and significantly increased plasma total antioxidant capacity (TAC) levels (β 106.07 mmol/L; 95% CI, 62.87, 149.28; P < 0.001) and total glutathione (GSH) (β 81.05 μmol/L; 95% CI, 36.08, 126.03; P = 0.001) compared with the placebo. Moreover, melatonin supplementation downregulated gene expression of interleukin-1 (IL-1) (P = 0.03) and tumor necrosis factor alpha (TNF-α) (P = 0.01) compared with the placebo. Conclusions: Overall, melatonin administration for 12 weeks to women with PCOS significantly reduced hirsutism, total testosterone, hs-CRP, and MDA, while increasing TAC and GSH levels. In addition, melatonin administration reduced gene expression of IL-1 and TNF-α. Clinical Trial Registration: www.irct.ir, identifier IRCT2017082733941N9, Available online at: https://www.irct.ir/trial/26051